There was a significant difference in the tumor-free time (P = 0.0031) observed between control PyMT transgenic mice (45.1 ± 9.6 days) and PyMT transgenic mice treated with FTY720, a PP2A activator (64.3 ± 11.4 days) (Fig. 7G), revealing a previously unknown therapeutic effect of this drug. The gene discussed is PTPA; the disease is neoplasm.